Clinical trial
A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
NCT05861999 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IV Open-Label Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- August 14, 2024
- Completion date
- March 31, 2029
- Enrollment
- 28 (estimated)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.